BCLI (Brainstorm Cell Therapeutics) Tariff Resilience Score: 5/10 (As of Jul. 13, 2026)


BCLI Brainstorm Cell Therapeutics Inc BCLI
28 GF Score
Price $1.00
! 2 Warning Signs
View Full Analysis

What is Brainstorm Cell Therapeutics Tariff Resilience Score?

Brainstorm Cell Therapeutics BCLI -7.41% 28 Tariff Resilience Score is 5 as of Jul. 13, 2026. GuruFocus rates BCLI with a GF Score™ of 28/100. The stock has 2 warning signs investors should review. Among 1,370 Biotechnology companies, Brainstorm Cell Therapeutics ranks better than 62.41% on this metric.

Brainstorm Cell Therapeutics has the Tariff Resilience Score of 5, which implies that the company might have Average Resilient.

Brainstorm Cell Therapeutics has Brainstorm Cell Therapeutics has moderate exposure due to its reliance on international clinical trials and supply chains. The biotech industry faces specific regulatory exemptions, but the company lacks significant pricing power to offset potential tariff impacts.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Brainstorm Cell Therapeutics might have Average Resilient.

Brainstorm Cell Therapeutics  (OTCPK:BCLI) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Brainstorm Cell Therapeutics Tariff Resilience Score Related Terms

BCLI vs ADAPY, APRE, JSPR: Tariff Resilience Score Comparison

For the Biotechnology subindustry, Brainstorm Cell Therapeutics's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Brainstorm Cell Therapeutics Tariff Resilience Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Brainstorm Cell Therapeutics's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where Brainstorm Cell Therapeutics's Tariff Resilience Score falls into.


BCLI
28GF Score
Brainstorm Cell Therapeutics Inc BCLI
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Tariff Resilience Score of 5 mean?
Brainstorm Cell Therapeutics (BCLI) has a Tariff Resilience Score of 5 as of Jul. 13, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, Brainstorm Cell Therapeutics ranks #515 out of 1370 companies in the Biotechnology industry, placing it in the top 37.6%.
Is Brainstorm Cell Therapeutics' Tariff Resilience Score too high?
Brainstorm Cell Therapeutics' current Tariff Resilience Score is 5. The Biotechnology industry median Tariff Resilience Score is 4.00. Brainstorm Cell Therapeutics' value of 5 is 25% above this industry median. Based on the distribution chart, Brainstorm Cell Therapeutics ranks #515 out of 1370 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Brainstorm Cell Therapeutics has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does Brainstorm Cell Therapeutics' Tariff Resilience Score compare to ADAPY and APRE?
According to the Biotechnology industry distribution chart, Brainstorm Cell Therapeutics ranks #515 out of 1370 companies for Tariff Resilience Score. This puts Brainstorm Cell Therapeutics in the upper half of its industry. The industry median Tariff Resilience Score is 4.00. Brainstorm Cell Therapeutics' value of 5 is 25% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Biotechnology company?
The median Tariff Resilience Score among Biotechnology companies is 4.00, based on 1,370 companies in the industry. Companies in the top quartile (top 25%) have a Tariff Resilience Score significantly above this median, while those in the bottom quartile fall well below. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Brainstorm Cell Therapeutics's current Tariff Resilience Score of 5 is 25% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. For the Biotechnology industry, the median Tariff Resilience Score is 4.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Brainstorm Cell Therapeutics's current Tariff Resilience Score is 5. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Brainstorm Cell Therapeutics stock overvalued right now?
Brainstorm Cell Therapeutics (BCLI) has a current Tariff Resilience Score of 5. The current Tariff Resilience Score is 5 and 25% above the Biotechnology industry median of 4.00. Brainstorm Cell Therapeutics' overall GF Score™ is 28/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For Brainstorm Cell Therapeutics (BCLI), the current Tariff Resilience Score is 5 as of Jul. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Brainstorm Cell Therapeutics Business Description

Address 1325 Avenue of Americas, 28th Floor, New York, NY, USA, 10019
Brainstorm Cell Therapeutics Inc is a biotechnology company committed to the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis, progressive multiple sclerosis, Alzheimer's disease, and other neurodegenerative diseases. NurOwn, its proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival and improve neurological function. The company has one reportable segment specializing in the development and commercialization of autologous cellular therapies for the treatment of ALS.
28GF Score

Get the complete analysis for BCLI

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.00
Price